Some investors might remember Inovio Pharmaceuticals (NASDAQ: INO); others might not. The small-cap biotech was once racing to develop an effective coronavirus vaccine. Its bet to become a leader in this field fell flat, the company largely fell into irrelevance, and its value decreased substantially. ...
motleyfoolusx:ino